NEOGENOMICS (NEO) - Holzer & Holzer

ATLANTA, GA – – (Newsfile Corp. – March 31, 2022) – – Holzer & Holzer, LLC is investigating whether NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) complied with federal securities laws. On March 28, 2022, the Company announced that its CEO was stepping down and further disclosed that it expects “revenue for Q1 2022 may be below the low end of its prior guidance of $118 – $120 million and EBITDA for Q1 2022 will be below the low end of its prior guidance of $(15) – $(12) million.” Following this announcement, the Company’s stock price dropped. If you purchased NeoGenomics stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

View Complaint

View Representation Agreement

Provide Your Information To Take Action

Name*
First Last
Email*
Phone*
Address*
Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country
Shares Purchased:*
Date Purchased Number of Shares Acquired Acquisition Price Per Share
Shares Sold:
Date Sold Number of Shares Sold Selling Price Per Share
By clicking on the button below, I intend to sign and execute this Agreement and retain Holzer & Holzer, LLC to proceed on my behalf.*
- I agree.
Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.
Signature*
CAPTCHA

Date Purchased	Number of Shares Acquired	Acquisition Price Per Share